Table 3 Ongoing antibody-drug conjugates for NSCLC in early-phase clinical trials.
From: Antibody-drug conjugates in lung cancer: dawn of a new era?
Drug | Target | Payload | ClinicalTrials.gov (Study Name) | Other solid tumors treated in early-phase clinical trials |
|---|---|---|---|---|
Trastuzumab Emtansine (TDM1) | HER2 | Emtansine (DM1) | NCT02289833 | Breast |
Trastuzumab Deruxtecan (DS-8201) | HER2 | Deruxtecan (DXd) | NCT04644227 (DESTINY-LUNG02) | Breast, gastric, gastro-esophageal, osteosarcoma, biliary tract, cervical, endometrial, ovarian, pancreas |
ARX788HE | HER2 | Monomethyl Auristatin F (MMAF) | NCT03255070 (ACE-Pan Tumor 01) | Breast, gastric |
Patritumab Deruxtecan | HER3 | Deruxtecan (DXd) | NCT04619004 (HERTHENA- Lung01) | Breast, colon, head & neck cancer |
Enapotamab-Vedotin (HuMax-AXL-ADC) | AXL | Vedotin (MMAE) | NCT02988817 | Ovarian, cervical, endometrial, thyroid, melanoma, sarcoma |
CAB-AXL-ADC (BA3011) | AXL | Vedotin (MMAE) | NCT04681131 | Pancreas, melanoma, sarcoma |
CX2029 | CD71 | Vedotin (MMAE) | NCT03543813 (PROCLAIM-CX-2029) | Head & neck, diffuse large b-cell lymphoma, esophageal |
Tusamitanib-Ravtansine (SAR408701) | CEACAM5 | Ravtansine (DM4) | NCT04154956 (CARMEN-LC03) NCT04524689 (CARMEN-LC05) | Breast, pancreas |
Mirvetuximab-Soravtansine (MIRV) | FRα | Soravtansine (DM4) | NCT01609556 | Ovarian, endometrial, fallopian tube, primary peritoneal, breast |
ELU-001 (FA-CDC) | FRα | C’Dot-Drug-Conjugate (CDC) | NCT05001282 | Ovarian, endometrial, peritoneal, colorectal, gastric, esophageal, breast, cholangiocarcinoma, biliary duct |
Datopotamab-Deruxtecan (DS-1062) | HER2 | Deruxtecan (DXd) | NCT04656652 (TROPION- Lung01) NCT04484142 (TROPION-Lung05) NCT03401385 (TROPION-PanTumor01) | Breast (triple-negative, hormone receptor positive/HER2-negative breast cancer), urothelial, gastric, esophageal |
RG7841 (DLYE5953A) | Ly6E | Vedotin (MMAE) | NCT02092792 | Breast, pancreas, ovarian |
Anetumab-ravtansine (BAY94-9343) | Mesothelin | Ravtansine (DM4) | NCT03102320 | Mesothelioma, ovarian, pancreas, breast |
Telisotuzumab vedotin (ABBV-399) | c-MET | Vedotin (MMAE) | NCT03539536 | Solid tumors |
Lifastuzumab-vedotin (RG- 7599, DNIB0600A) | NaPi2b | Vedotin (MMAE) | NCT01363947 NCT01995188 | Ovarian |
Upifitamab-Rilsodotin (XMT-1536) | NaPi2b | Rilsodotin (AF- HPA) | NCT03319628 (UPLIFT) | Ovarian |
Enfortumab-vedotin (ASG- 22CE) | Nectin-4 | Vedotin (MMAE) | NCT04225117 | Urothelial, breast, head & neck, gastric, gastro-esophageal, esophageal, prostate, ovarian |
Tisotumab vedotin (HuMax- TF-ADC) | Tissue Factor (TF) | Vedotin (MMAE) | NCT03245736 NCT01631552 | Cervical, ovarian, endometrial, bladder, prostate, esophageal |
Sacituzumab govitecan (IMMU-132, hRS7-SN-38) | Trop2 | Govitecan (SN-38) | NCT03964727 (TROPiC S-03) NCT03337698 (Morpheus Lung) | Breast, head & neck, endometrial, gastric, esophageal, hepatocellular, ovarian, prostate, bladder, renal cell, cervical, pancreas, GBM |
Naptumomab-estafentanox (NAP, ABR-217620, Anyara) | Staphlococcal enterotoxin A and 5 T4 (TPBG) | Immune-conjugate | NCT04880863 (NT-NAP-102–1) | Renal cell, pancreas |
Cofetuzumab-pelidotin (ABBV-647, PF- 06647020) | PTK7 | Pelidotin (Aur0101) | NCT04189614 | Breast, ovarian |
Trastuzumab-duocarmazine (SYD985) | HER2 | Duocarmazine | NCT04235101 | Breast, ovarian, endometrial |
MORAb-202 (Farletuzumab Linked to Eribulin Mesylate) | Folate Receptor-α | Eribulin | NCT03386942 | Solid tumors |
